Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Individualized, PK-Guided Dosing of Hydroxyurea for Young Children with Sickle Cell Anemia: Final Results from the Hydroxyurea Optimization through Precision Study (HOPS)

Abena Appiah-Kubi, Seethal A Jacob, Matthew M. Heeney, Connie M. Piccone, Omar Niss, Charles T. Quinn, Stephanie A. Fritch Lilla, Maa-Ohui Quarmyne, Angeli Rampersad, Allison Remiker, Amy Tang, Min Dong, Kathryn McElhinney, Joshua R. Tanzer, Patrick T. McGann

Blood (2024) 144 (Supplement 1): 175.

https://doi.org/10.1182/blood-2024-200426

Published: 2024

Journal Articles

Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts

Alexandra Power-Hays, Kathryn E. McElhinney, Teresa S. Latham, Tom N. Williams, George Mochamah, Peter Olupot-Olupot, George Paasi, Marvin Ellsworth Reid, Angela Rankine-Mullings, Robert Opoka, Chandy C. John, Patrick T. McGann, Charles T. Quinn, Susan E. Stuber, Russell E. Ware

Blood (2024) 144 (Supplement 1): 542.

https://doi.org/10.1182/blood-2024-201577

Published: 2024

Journal Articles

Location, Location(s), Location(s+): Moving from Acute to Chronic Pain in SCD Pain in School-Age Children

Bridget N Murphy, Anna M Hood, Aimee K. Hildenbrand, Lisa M Shook, Charles T. Quinn, Erin Smoot, Soumitri Sil, Lori E. Crosby

Blood (2024) 144 (Supplement 1): 5360.

https://doi.org/10.1182/blood-2024-194912

Published: 2024

Journal Articles

Underutilization of Disease-Modifying Therapies in Sickle Cell Disease: A Real-World Analysis from the ASH Research Collaborative Data Hub

Omar Niss, Matthew Fenchel, Erin Kingsley, Teresa S. Latham, Punam Malik, Charles T. Quinn

Blood (2024) 144 (Supplement 1): 2312.

https://doi.org/10.1182/blood-2024-206015

Published: 2024

Journal Articles

Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)-an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain

Blood (2024) 144 (Supplement 1): 291.

https://doi.org/10.1182/blood-2024-209083

Published: 2024

Journal Articles

Longitudinal Assessment of Myocardial Fibrosis in Sickle Cell Disease

Omar Niss, Cara Morin, Sean M Lang, Tarek Alsaied, MacKenzie Tasset, Punam Malik, Charles T. Quinn

Blood (2024) 144 (Supplement 1): 799.

https://doi.org/10.1182/blood-2024-200951

Published: 2024

Journal Articles

Patterns of Nonadherence to Hydroxyurea in Pediatric Sickle Cell Disease

Lori E. Crosby, Amy Lang, Constance Mara, Charles T. Quinn, Corinna L. Schultz, Benjamin Bear, Tinuke E. Akintobi, Robin E. Miller, Aimee K. Hildenbrand

Blood (2023) 142 (Supplement 1): 7198.

https://doi.org/10.1182/blood-2023-187611

Published: 2023

Journal Articles

Association between Acute Pain Scores in Children with Sickle Cell Disease and Emergency Department Disposition and Return Visit Rates

Blood (2023) 142 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2023-180273

Published: 2023

Journal Articles

Effects of L-Glutamine on Biomarkers of Response in Sickle Cell Disease: A Pharmacokinetics-Pharmacodynamics Analysis

Alina Sadaf, Min Dong, Jennifer Korpik, Amanda Pfeiffer, Theodosia A. Kalfa, Teresa S. Latham, Alexander A. Vinks, Russell E. Ware, Charles T. Quinn

Blood (2023) 142 (Supplement 1): 1145.

https://doi.org/10.1182/blood-2023-180312

Published: 2023

Journal Articles

Hydroxyurea: how much is enough?

Charles T. Quinn

Blood (2023) 141 (8): 813–814.

https://doi.org/10.1182/blood.2022018790

Published: 2023

Journal Articles

Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes

Blood (2022) 140 (Supplement 1): 5418–5419.

https://doi.org/10.1182/blood-2022-166132

Published: 2022

Journal Articles

Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial

Abena Appiah-Kubi, Seethal A Jacob, Matthew M. Heeney, Clark Brown, Susan E. Creary, Christine R Hollenkamp, Emily Riehm Meier, Omar Niss, Connie M. Piccone, Maa-Ohui Quarmyne, Charles T. Quinn, Allison Remiker, Kay L Saving, Min Dong, Patrick T. McGann

Blood (2022) 140 (Supplement 1): 5416–5417.

https://doi.org/10.1182/blood-2022-158623

Published: 2022

Journal Articles

Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia

Blood (2022) 140 (Supplement 1): 10857–10859.

https://doi.org/10.1182/blood-2022-167914

Published: 2022

Journal Articles

Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis

Min Dong, Alina Sadaf, Alexander A. Vinks, Russell E. Ware, Charles T. Quinn

Blood (2022) 140 (Supplement 1): 8256–8257.

https://doi.org/10.1182/blood-2022-167550

Published: 2022

Journal Articles

Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia

Omar Niss, Jon Detterich, John C. Wood, Thomas D. Coates, Punam Malik, Michael D. Taylor, Charles T. Quinn

Blood (2022) 140 (11): 1322–1324.

https://doi.org/10.1182/blood.2021015303

Published: 2022

Includes: Supplemental data

Journal Articles

Reproductive equity: preserve the reserve

Charles T. Quinn, Russell E. Ware

Blood (2022) 139 (7): 963–965.

https://doi.org/10.1182/blood.2021015021

Published: 2022

Journal Articles

Pharmacokinetics of L-Glutamine (Endari) in Pediatric and Adult Sickle Cell Disease Patients: A Phase 4, Open-Label, Single-Center Study

Alina Sadaf, Min Dong, Amanda Pfeiffer, Teresa Latham, Alexander A. Vinks, Russell E. Ware, Charles T. Quinn

Blood (2021) 138 (Supplement 1): 980.

https://doi.org/10.1182/blood-2021-147631

Published: 2021

Journal Articles

Effects of the COVID-19 Pandemic on Caregivers of Young Children with Sickle Cell Disease Enrolled in the Engage-HU Trial

Blood (2021) 138 (Supplement 1): 1891.

https://doi.org/10.1182/blood-2021-152722

Published: 2021

Journal Articles

Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning

Michael Grimley, Monika Asnani, Archana Shrestha, Sydney Felker, Carolyn Lutzko, Paritha I. Arumugam, Scott Witting, Jennifer Knight-Madden, Omar Niss, Charles T. Quinn, Chris Lo, Courtney R. Little, Alisa Dong, Punam Malik

Blood (2021) 138 (Supplement 1): 3970.

https://doi.org/10.1182/blood-2021-147469

Published: 2021

Journal Articles

Increased oxygen affinity: to have and to hold

Charles T. Quinn, Russell E. Ware

Blood (2021) 138 (13): 1094–1095.

https://doi.org/10.1182/blood.2021013243

Published: 2021

NARROW

Individualized, PK-Guided Dosing of Hydroxyurea for Young Children with Sickle Cell Anemia: Final Results from the Hydroxyurea Optimization through Precision Study (HOPS)

Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts

Location, Location(s), Location(s+): Moving from Acute to Chronic Pain in SCD Pain in School-Age Children

Underutilization of Disease-Modifying Therapies in Sickle Cell Disease: A Real-World Analysis from the ASH Research Collaborative Data Hub

Integrative Strong Body and Mind Training for Sickle Cell Disease (I-STRONG)-an Interdisciplinary, Multicomponent Treatment Approach for Pediatric Chronic SCD Pain

Longitudinal Assessment of Myocardial Fibrosis in Sickle Cell Disease

Patterns of Nonadherence to Hydroxyurea in Pediatric Sickle Cell Disease

Association between Acute Pain Scores in Children with Sickle Cell Disease and Emergency Department Disposition and Return Visit Rates

Effects of L-Glutamine on Biomarkers of Response in Sickle Cell Disease: A Pharmacokinetics-Pharmacodynamics Analysis

Hydroxyurea: how much is enough?

Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes

Individualized, PK-Guided Dosing of Hydroxyurea Is Not Associated with Increased Hematologic Toxicity Compared to Weight-Based Initial Dosing: Interim Results from the Hops Trial

Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia

Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis

Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia

Reproductive equity: preserve the reserve

Pharmacokinetics of L-Glutamine (Endari) in Pediatric and Adult Sickle Cell Disease Patients: A Phase 4, Open-Label, Single-Center Study

Effects of the COVID-19 Pandemic on Caregivers of Young Children with Sickle Cell Disease Enrolled in the Engage-HU Trial

Safety and Efficacy of Aru-1801 in Patients with Sickle Cell Disease: Early Results from the Phase 1/2 Momentum Study of a Modified Gamma Globin Gene Therapy and Reduced Intensity Conditioning

Increased oxygen affinity: to have and to hold

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only